The ultrasensitive PSA assay has been recently acknowledged as a useful tool for the monitoring of patients prostatectomized for prostatic cancer. We have evaluated a commercially available ultrasensitive PSA assay (Immulite Third Generation PSA-DPC-Los Angeles CA) in comparison with the routinely used PSA (Immulite PSA-DPC-Los Angeles CA). When evaluated with different approaches, the analytical sensitivity of ultrasensitive PSA ranged between 0.0029 and 0.0038 ng/ml. The biological detection limit was 0.0098 ng/ml. Dilution of samples with low PSA levels showed a good recovery (from 88 to 113%) up to 1:128 dilution factor (final PSA levels ranging from 0.004 to 0.016 ng/ml in different samples). The assay precision was excellent in the low dose range, the highest interassay interadjustment CV among replicates being 5.84% when assaying serum samples with PSA lower than 1.0 ng/ml. Besides its role in the follow-up of prostatectomized patients, the evaluated ultrasensitive PSA could be reliably used for the detection of clinically meaningful PSA variations in the low dose range, and it could therefore be a candidate for the assessment of PSA velocity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/172460089501000408 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk assessment of late biochemical recurrence after radical prostatectomy: Usefulness of ultra-sensitive prostate-specific antigen measurement.
Int J Urol
December 2024
Department of Urology, Osaka International Cancer Institute, Osaka, Japan.
Objectives: This study aimed to evaluate predictors of late biochemical recurrence in patients with no recurrence at 5 years after radical prostatectomy (RP).
Methods: We retrospectively investigated patients who underwent RP for prostate cancer in our institute from 1999 to 2016, selecting those with no biochemical recurrence at 5 years post-RP. These patients did not receive neoadjuvant and adjuvant hormone therapy.
Real-Time and Ultrasensitive Prostate-Specific Antigen Sensing Using Love-Mode Surface Acoustic Wave Immunosensor Based on MoS@CuO-Au Nanocomposites.
Sensors (Basel)
November 2024
Shenzhen Key Laboratory of Advanced Thin Films and Applications, GuangDong Engineering Technology Research Centre of Breath Test, College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China.
Prostate-specific antigen (PSA) is a well-established tumour marker for prostatic carcinoma. In this study, we present a novel, real-time, and ultrasensitive Love-mode surface acoustic wave (L-SAW) immunosensor for PSA detection enhanced by MoS@CuO-Au nanocomposite conjugation. The MoS@CuO-Au nanocomposites were analyzed by SEM, XRD, and EDS.
View Article and Find Full Text PDFObjectives: To assess the role of ultrasensitive PSA values (usPSA) after radical prostatectomy in predicting the subsequent biochemical recurrence (BCR).
Material And Methods: The study included 1836 patients who underwent open or robot-assisted RP at Turku University Hospital between 2003 and 2018. Exclusion criteria involved patients with adjuvant treatments and those who did not reach a PSA nadir <0.
Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database.
Eur Urol Open Sci
December 2024
Instituto Valenciano de Oncología, Valencia, Spain.
Background And Objective: The depth of the prostate-specific antigen (PSA) decline after androgen receptor pathway inhibitor (ARPI) treatment combined with androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC) may affect prognosis. The primary objective in our study was the correlation between the PSA response at 3 mo and radiologic progression-free survival (rPFS) at 24 mo. Three groups were defined according to the PSA decline: complete response (PSA ≤0.
View Article and Find Full Text PDFA paper-in-polymer-pond (PiPP) hybrid microfluidic microplate for multiplexed ultrasensitive detection of cancer biomarkers.
Lab Chip
October 2024
Department of Chemistry & Biochemistry, University of Texas at El Paso, 500 W University Ave, El Paso, TX, USA.
Article Synopsis
- Conventional ELISA methods for detecting cancer biomarkers face challenges like long incubation times, high reagent requirements, and low sensitivity.
- A new paper-in-polymer-pond (PiPP) hybrid microfluidic microplate has been developed to allow quick, cost-effective, and sensitive detection of disease biomarkers in under an hour without the need for sophisticated equipment.
- The device achieves improved sensitivity and can be reused by replacing the paper layer, enabling better efficiency in reagent delivery and quantitative analysis using common imaging tools like scanners or smartphone cameras.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!